FDA Approves Prademagene Zamikeracel, First and Only Cell-Based Gene Therapy for Recessive Dystrophic Epidermolysis Bullosa

Source: Pharmacy Times articles

FDA approves Zevaskyn, the first gene therapy for RDEB, offering hope for effective wound healing and pain relief in patients.
Read More